[Molsidomine in ergometric tests (author's transl)].
The effect of 2 mg sublingual molsidomine was evaluated in a double-blind cross-over study and compared to placebo in 9 patients with stable angina pectoris and ST-lowering of greater than or equal to 1 mm in the exercise ECG. Assessment of exercise tolerance (Watt-minute product) and ST-lowering during exercise with the bicycle ergometer was correlated with simultaneously measured blood plasma levels. An increase of maximal Watt-minute product from mean = 308.3 (s mean - 45.4) to mean = 74.4 (s mean = 138.7) was found after 1 hour with effectiveness over 5 hours. ST-lowering while on molsidomine was decreased from mean = 2.5 mm (s mean = 0.3) to a minimum of mean = 0.7 mm (s mean = 0.28) during identical work load. Action on the ST segment lasted for 3 hours. Blood plasma levels of molsidomine correlated to the drug action with a maximum after one hour and a half life of 2.03 hours.
D000787:Angina Pectoris / Q000175:diagnosis / Q000188:drug therapy*; D004311:Double-Blind Method; D005080:Exercise Test; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D008875:Middle Aged; D008981:Molsidomine; D009025:Morpholines / Q000097:blood / Q000627:therapeutic use*; D010069:Oxadiazoles / Q000627:therapeutic use*; D010919:Placebos; D013558:Sydnones / Q000097:blood / Q000627:therapeutic use*; D013997:Time Factors
D009025:Morpholines; D010069:Oxadiazoles; D010919:Placebos; D013558:Sydnones; D008981:Molsidomine
Molsidomin im Ergometerversuch. Korrelation von Wirkung und Blutplasmaspiegel.